A coronavirus vaccine candidate developed by the Chinese Academy of Sciences (CAS) was found to be safe and triggered immune responses in early and mid-stage trials, researchers said on Tuesday.
CAS, a division of the American Chemical Society, announced that leading contract research, development and manufacturing organization (CRO/CDMO) BioDuro has signed a five-year agreement for SciFindern.